NEWSROOM Press Releases

    254 Results

    Biodesix Announces Third Quarter 2023 Results and Highlights

    Biodesix Inc. announced its financial and operating results for the third quarter ended September 30, 2023 and provided a corporate update.

    Robin Harper Cowie Appointed to Colorado BioScience Association's Board of Directors

    Biodesix, Inc. is proud to announce that its CFO, Robin Harper Cowie, has been appointed to the Colorado BioScience Association (CBSA) board of directors.

    Biodesix to Report Second Quarter 2023 Financial Results on August 7, 2023

    Biodesix announced today that it will release financial results for the second quarter ended June 30, 2023 after the close of trading on Monday, August 7.

    Biodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023

    Biodesix’s management will host a conference call and webcast to discuss its financial results and provide a general business update.

    Biodesix to Present New Data on Nodify Lung® Testing at CHEST 2023 Annual Meeting

    Discover key insights from Biodesix at CHEST 2023 on Nodify Lung® tests, impacting pulmonary nodule management and reducing invasive procedures.

    Biodesix to Participate in William Blair’s 43rd Annual Growth Stock Conference

    Scott Hutton, Chief Executive Officer of Biodesix, will present and host in-person 1x1 investor meetings at William Blair’s 43rd Annual Growth Stock Conference, which will be held from June 6-8, 2023.

    Biodesix to Participate in Two Upcoming Investor Conferences in September

    Scott Hutton, Chief Executive Officer of Biodesix, will participate in two upcoming investor conferences: Morgan Stanley 21st Annual Global Healthcare Conference and H.C. Wainwright 25th Annual Global Investment Conference.

    Biodesix to Participate in Two Upcoming Investor Conferences in November

    Biodesix announced Scott Hutton, CEO, will participate in two upcoming investor conferences: Canaccord Genuity Medtech, Diagnostics, Digital Health & Services Forum and Piper Sandler 35th Annual Healthcare Conference

    Biodesix Enhances Access to Nodify Lung® Testing with Launch of New Blood Draw Method

    Biodesix announced today the validation and launch of a new method of collecting blood specimens for Nodify Lung Nodule Risk Assessment testing.

    Biodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

    Biodesix announced today that the prospective, real-world ORACLE study (An Observational Registry Study to Evaluate the Performance of the Nodify XL2® Test [NCT03766958]) achieved the primary endpoint of a statistically significant change in the proportion of benign lung nodules managed by Nodify XL2® experiencing invasive procedures.

    Biodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® Testing

    Biodesix presented original data in four separate poster presentations at the ISPOR (International Society for Pharmaceutical and Outcomes Research) conference, providing evidence of the health economic benefits of the Nodify CDT® and Nodify XL2® tests in the management of pulmonary nodules.

    Biodesix to Report Third Quarter 2023 Financial Results on November 7, 2023

    Biodesix announced today that it will release financial results for the third quarter ended September 30, 2023 after the close of trading on Tuesday, November 7.

    Biodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

    Biodesix reveals key NSCLC proteomic test data at IASLC 2023, highlighting VeriStrat's predictive power and the Risk of Recurrence test's precision

    Biodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

    Biodesix reveals ORACLE study results: Nodify XL2 test effectively identifies benign lung nodules, leading to a 51% increase in lung cancer diagnosis rates and fewer invasive procedures.

    Biodesix Announces Second Quarter 2023 Results and Highlights

    Biodesix Q2 2023: Core Lung Diagnostic revenue at $11.4M (up 58% YoY), 73% profit margin. 2023 guidance: $52-55M. $27.5M private shares sold.

    Biodesix Participates in Canaccord Genuity Annual Growth Conference

    Biodesix CEO to present at Canaccord Genuity's 43rd Annual Growth Conference on Aug 9, 2023. Discover data-driven lung disease solutions at Biodesix.com.

    Biodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

    Biodesix announces the designation of its Nodify CDT Test as an Advanced Diagnostic Laboratory Test by CMS, recognizing its innovation and clinical value in assessing the risk of malignancy in pulmonary nodules

    Biodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune Classifier

    INSIGHT study monitors 5,000 NSCLC patients for 3 years, validating VeriStrat® test. Biodesix: leading lung disease diagnostic solutions.

    Biodesix Announces First Quarter 2023 Results and Highlights

    Biodesix reports Q1 2023 results: 86% increase in Core Lung Diagnostic revenue, record test numbers, and reaffirms 2023 financial outlook.

    Biodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual Meeting

    three new scientific abstracts will be presented as part of the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting including a poster presented by Friends of Cancer Research (FoCR)

    Biodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

    Biodesix announces new clinical utility data highlighting the impact of the Nodify XL2 Risk Assessment Test on clinical management decisions in patients with lung nodules will be presented at the American Thoracic Society (ATS) 2023 International Conference.

    Biodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and Highlights

    Biodesix announces its financial and operating results for the fourth quarter and year ended December 31, 2022 (fiscal 2022) and provided a corporate update.

    Biodesix to Participate at Cowen’s 43rd Annual Healthcare Conference

    Scott Hutton, Chief Executive Officer of Biodesix, will participate in a fireside chat and host in-person investor meetings at Cowen’s 43rd Annual Healthcare Conference.